曲美他嗪治疗缺血性心力衰竭临床观察.docVIP

曲美他嗪治疗缺血性心力衰竭临床观察 　　[摘要] 目的 观察曲美他嗪治疗缺血性心力衰竭的临床疗效。 方法 将70例缺血性心力衰竭患者随机分为治疗组35例和对照组35例，对照组给予常规治疗，治疗组在对照组治疗基础上加用曲美他嗪，两组疗程均为3个月。观察比较两组临床疗效、左室舒张末期容积（LVEDD）、左室射血分数（LVEF）和6 min步行距离。 结果 治疗组的临床疗效、LVEDD、LVEF及6 min步行距离均明显优于对照组，差异有统计学意义（P 0.05）。结论 曲美他嗪治疗缺血性心力衰竭疗效显著，能明显改善患者心脏的收缩功能，值得临床推广使用。 　　[关键词] 曲美他嗪；缺血性心力衰竭；治疗 　　[中图分类号] R972；R541 [文献标识码] A [文章编号] 1673-7210（2012）04（a）-0063-02 　　 　　Clinical observation of Trimetazidine in the treatment of ischemic heart failure 　　CHEN Li 　　Department of Cardiology, Armed Police Corps Headquarters Hospital, Xinjiang Uygur Autonomous Region, Urumchi 830 063, China 　　[Abstract] Objective To observe the therapeutic efficacy of Trimetazidine in the treatment of ischemic heart failure. Methods 70 cases of patients with ischemic heart failure were randomly assigned to the treatment group of 35 patients and the control group of 35 patients. Patients in the control group were given conventional therapy, while patients in the treatment group were given Trimetazidine on the basis of conventional therapy. Both groups were treated for 3 months. Clinical efficacy, left ventricular end-diastolic volume (LVEDD), left ventricular ejection fraction (LVEF) and 6-minute walking distance of the two groups were observed and compared. Results The clinical efficacy, LVEDD, LVEF and 6-minute walking distance of the treatment group were significantly better than that of the control group, the differences were statistically significant (P 0.05). Conclusion Trimetazidine has significant treatment effect on ischemic heart failure by significantly improving cardiac contractile function, thus it is worthy of clinical application. 　　[Key words] Trimetazidine; Ischemic heart failure; Treatment 　　 　　缺血性心力衰竭（IHD）是内科常见的严重临床综合征，是缺血性心脏病致残、致死的重要原因[1]。曲美他嗪是治疗心绞痛和心功能不全等心血管疾病的常用辅助药物，在优化心肌能量代谢方面具有较好的效果，尤其适用于治疗心肌缺血性疾病。近年来我科37例缺血性心力衰竭患者通过常规治疗同时配伍曲美他嗪，取得了较好的临床疗效，现总结报道如下： 　　1 资料与方法 　　1.1 一般资料 　　本组70例均为2008年1月~2010年1月我科诊治的缺血性心力衰竭患者，其中，男46例，女24例，年龄60~78岁，平均73.5岁。所有患者均符合WHO关于缺